ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1385 National Cancer Institute Html en Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Health Professional Version Expert-reviewed information summary about factors that may influence the risk of developing ovarian, fallopian tube, and primary peritoneal cancers and about research aimed at the prevention of them.
oral contraceptives0.660699
untreated subfertile women0.554695
population-based case-control study0.569591
multiple case-control studies0.577558
tubal ligation0.612813
ovarian cancer subtypes0.638647
endometrioid carcinomas0.557685
Ovarian Cancer Association0.647707
invasive ovarian tumors0.625952
tubal intraepithelial carcinoma0.613375
case-control studies0.724549
modest increased risk0.571056
ovarian cancer0.933826
clear cell carcinomas0.577194
oral contraceptive therapy0.556361
ovarian carcinoma0.65109
ovarian reserve0.599754
ovarian borderline tumor0.646023
low-grade ovarian carcinomas.0.649208
ovarian primary tumors.0.639278
high-grade carcinomas0.568553
cohort studies0.697042
hospital-based case-control studies0.582441
ovarian cancer cases0.640486
epithelial ovarian cancers0.62928
women0.680224
borderline ovarian tumors0.627194
prospective cohort studies0.573074
risk reduction0.631051
cohort study0.558817
ovarian carcinomas0.707015
clear cell cancer0.56063
ovarian cancers0.642329
unexposed infertile women0.555673
observed risk reduction0.618238
ovarian hyperstimulation0.617463
significant increased risk0.567639
high-grade serous carcinomas0.73533
fallopian tube0.554218
epithelial ovarian cancer0.644523
ovarian cancer risk0.740549
epidemiological studies0.565
population-based case-control studies0.621559
gastrointestinal primary tumors0.557125
Netherlands cohort study0.55691
ovarian carcinoma subtypes0.642907
meta-analysis0.563338
systematic review0.583056
CLICK HERE
1387 National Cancer Institute Html en Breast Cancer Prevention (PDQ®)–Health Professional Version Risk factors for breast cancer are female sex and advancing age, inherited risk, breast density, obesity, alcohol consumption, and exposure to ionizing radiation. Interventions to prevent breast cancer include chemoprevention (e.g. SERMs, AIs), risk-reducing surgery (e.g. mastectomy, oophorectomy). Review the evidence on risk factors and interventions to prevent breast cancer in this expert-reviewed summary.
Surgical Adjuvant Breast0.484835
situ breast cancer0.497037
Breast Cancer Intervention0.493501
breast cancer trends0.484079
breast cancer deaths0.490132
radiation-associated breast cancer0.489257
Engl J Med0.493511
post-menopausal breast cancer0.480461
Breast Cancer Surveillance0.4815
breast cancer incidence.0.495634
treatment-related breast cancer0.489379
early-stage breast cancer0.507669
fatal breast cancer0.490061
ER-positive breast cancer0.490928
breast cancer prevention0.509672
Breast Cancer Collaborative0.483305
breast cancer patients0.502781
postmenopausal breast cancer0.486608
therapy-related breast cancer0.480826
breast cancer risk.0.512722
Natl Cancer Inst0.684414
-negative breast cancer0.484014
breast cancer death0.482095
invasive breast cancer0.614612
et al.0.488773
Swedish breast cancer0.480364
women0.553885
contralateral breast cancer0.510667
early breast cancer0.491581
age-specific breast cancer0.483209
breast cancer susceptibility0.482582
breast cancers0.487583
age-adjusted breast cancer0.485699
breast cancer rates0.491912
human breast cancer0.484504
tamoxifen breast cancer0.487689
Female Breast Cancer0.482581
postmenopausal women0.549947
breast cancer risk0.650399
International Breast Cancer0.494317
Abstract0.524687
breast cancer0.96573
breast cancer mortality0.521549
breast cancer cases0.492675
Breast Cancer Study0.481834
ER-negative breast cancer0.487382
breast cancer incidence0.616078
elevated breast cancer0.489604
Excess breast cancer0.489271
CLICK HERE
1412 National Cancer Institute Html en Lung Cancer Prevention (PDQ®)–Patient Version Expert-reviewed information summary about factors that may influence the risk of developing lung cancer and about research aimed at the prevention of this disease.
skin cancer0.349544
cancer treatment0.344722
cancer prevention trials0.366779
lung cancer screening0.424963
lung cancer prevention0.444623
prevention clinical trials0.358195
protective factors0.365293
following PDQ summaries0.35677
PDQ cancer information0.428189
lung cancer0.930545
clinical trials0.420475
secondhand smoke0.364049
important risk factor0.350351
cancer information summary0.398033
small cell lung0.428578
left lung0.393411
breast cancer prevention0.35675
cancer patients0.344267
cancer risk factor0.388012
low-dose spiral ct0.356728
NCI PDQ cancer0.3773
radiation therapy0.36772
new cases0.35557
CT scans0.355102
cancer risk factors0.383293
cancer protective factor0.369464
smokers0.342644
Atomic bomb radiation0.359839
Cancer Information Service0.361682
spiral CT scans0.353441
common cancer0.34956
smoking0.374366
Prevention Editorial Board0.360434
lower their risk0.346462
National Cancer Institute0.402346
new lung cancers0.398324
smoking low tar0.343862
Cancer Care page0.356844
right lung0.388076
non-small cell lung0.429832
people0.358421
PDQ summary0.34571
cancer -causing agents0.363798
cancer clinical trials0.36639
cell lung cancer0.479294
risk factors0.409463
cancer information summaries0.364825
comprehensive cancer information0.364576
CLICK HERE
1698 National Cancer Institute Html en Topics in Integrative, Alternative, and Complementary Therapies (PDQ®)–Patient Version Expert-reviewed information summary that contains information on integrative, complementary, and/or alternative therapies for people with cancer.
treatment0.496567
cancer treatment0.492995
cancer prevention0.491725
Complementary Therapies Editorial0.451339
Cancer Information Specialist0.463468
cancer cells0.485902
section0.463945
Cancer Information Service0.487907
Herbs/Dietary Supplements section0.454711
Cancer Complementary0.464741
breast cancer section0.455211
CAM therapies0.453618
specific PDQ summary0.507776
dietary supplements0.518422
National Cancer Institute0.533776
studies0.454937
clinical trials0.547318
cancer information summary0.522295
alternative medicine0.513784
PDQ documents0.462433
alternative cancer therapies0.45948
clinical trial0.455001
prostate cancer cells0.455068
CAM cancer research0.449455
PDQ health0.555354
PDQ summaries0.468855
cancer patients0.523763
PDQ database0.46397
PDQ Topics0.462207
fight cancer0.449901
breast cancer0.455561
prostate cancer patients0.471774
NCI’s PDQ0.468435
PDQ summary0.513781
professional summary0.498282
body fight cancer0.448775
NCI PDQ cancer0.502954
cancer information database0.46436
prostate cancer0.542459
complementary therapies0.470524
alternative therapies0.455648
hot flashes0.501425
cancer information summaries0.489288
cancer0.694704
information0.593851
PDQ Integrative0.464074
PDQ patient summary0.974252
CLICK HERE
1840 National Cancer Institute Html es Tratamiento de la enfermedad trofoblástica de la gestación (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento de la enfermedad trofoblástica de la gestación.
Obstet Gynecol0.314049
calificación pronóstica0.330592
Agarwal R0.309981
gestational trophoblastic tumor0.470216
gynecologic oncology0.31949
gestational trophoblastic tumour0.330225
Sin embargo0.495025
largo plazo0.308011
drug-resistant gestational trophoblastic0.316646
trophoblastic tumor simulating0.31025
gestational trophoblastic0.969098
high-risk gestational trophoblastic0.417868
site trophoblastic tumor0.331006
Epithelioid trophoblastic tumor0.331525
oncology group study0.309029
retrospective observational study0.310708
trophoblastic neoplasia with0.311489
trophoblastic tumor0.525373
newlands es0.321142
gestational trophoblastic neoplasia0.524164
Gynecol Oncol0.321149
Database Syst Rev0.308864
placental site trophoblastic0.326491
chemorefractory gestational trophoblastic0.316598
Reprod Med0.395131
gynecologic oncology group0.309183
Lancet Oncol0.308542
Organización Mundial0.310432
tumores trofoblásticos epitelioides0.326002
Lurain JR0.332449
metastatic gestational trophoblastic0.30963
Holden L0.308229
Cancer Staging Manual0.311272
Féderation Internationale0.320433
trophoblastic disease0.450228
with gestational trophoblastic0.311191
trophoblastic tumours0.335737
Recurrent gestational trophoblastic0.309132
Clin Oncol0.324887
sistema nervioso central0.319546
low-risk gestational trophoblastic0.340233
Charing Cross0.316962
Gynaecol Obstet0.314146
persistent gestational trophoblastic0.309878
Short D0.308931
FIGO Committee0.309443
Charing Cross Hospital0.309844
Obstet Gynaecol0.310271
AJCC Cancer Staging0.31188
CLICK HERE
1857 National Cancer Institute Html es Tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto.
ominosa situación0.323583
microscopic findings with0.340934
poorly differentiated tumors0.343157
cisplatin-based combination chemotherapy0.340177
unknown primary site0.370765
N)a aReproducción0.321827
Instituto Nacional0.378061
Radiat Oncol Biol0.947729
bUna designación0.320629
emission tomography with0.337851
Diagn Pathol0.32218
chemoradiotherapy using0.320607
solid tumors0.321716
Acta Cytol0.320567
Head Neck Surg0.377028
primary site0.383303
after excisional biopsy0.335976
metastases from0.417556
dysfunction following radiotherapy0.335828
carcinoma nasofaríngeo0.419271
Kahn HJ0.320427
paciente varón0.325653
cervical lymph0.356026
Recent progress0.321743
intensity-modulated radiotherapy0.356033
Cheung R0.361917
from unknown primary0.367172
National Cancer Institute0.343401
PDQ Tratamiento0.380147
nasopharyngeal carcinoma0.428219
Lombardi Comprehensive Cancer0.345987
Clin Oncol0.335468
unknown primary0.700357
Physician Data Query0.330819
enfermedad n20.320558
Oncol Biol Phys0.999042
enfermedad n10.322779
largo plazos0.351849
metastatic adenocarcinomas0.360803
unknown primary tumor0.440765
Induction chemotherapy with0.342645
Gray GF Jr0.331989
neck cancer0.546903
American Joint Committee0.331644
Reimann BE0.320391
Miyazaki I0.364645
AJCC Cancer Staging0.353491
squamous cell carcinoma0.742589
solitary metastatic neck0.365007
CLICK HERE
1973 National Cancer Institute Html es Tratamiento del cáncer de glándulas salivales (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del cáncer de glándulas salivales.
Neck Cancer0.247421
siguientes procedimientos0.717657
siguientes aspectos0.315855
estadio ii0.901856
vía oral0.251714
rayos x0.574567
pequeñas marcas0.24571
enlace drugs approved0.287895
exploración tac0.270837
National Cancer Institute0.238285
siguientes riesgos0.235555
Instituto Nacional0.352284
malla ayuda0.248945
PDQ Tratamiento0.283565
partículas minúsculas0.2536
radioterapia envía neutrones0.431263
presente sección0.245937
explorador tep0.281651
Physician Data Query0.352077
estadio iii0.736431
principales cánceres0.411638
siguientes situaciones0.301582
ganglio linfático mide0.91402
cáncer.ampliar radioterapia0.391316
siguientes enlaces0.247009
siguientes pruebas0.31121
CLICK HERE
3652 National Cancer Institute Html es Cannabis y canabinoides (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer, como la náusea y el vómito.
Natl Acad Sci0.394203
cannabinoid receptor cb20.362796
Neck Cancer Epidemiology0.340717
with peripheral cb10.353749
accessed october0.451422
receptores cb20.414613
Sin embargo0.375752
receptores cb10.617059
Mol Cancer Ther0.460254
cb2 receptors0.369543
marijuana as0.341164
potencial receptor0.334026
cannabinoid cb10.353877
Nat Rev Cancer0.38837
receptor cb20.381409
receptor cb10.494644
endogenous cannabinoid0.347836
Cancer Res0.471447
Pharmacol Biochem Behav0.366013
Marihuana Tax Act0.373003
cannabinoid receptor activation0.352792
lesiones premalignas0.350108
cannabinoid receptor with0.35689
Estados Unidos0.902915
endogenous cannabinoid system0.33287
Pain Symptom Manage0.358772
endocannabinoid system as0.404957
Integrating cannabis0.433732
Pharmacol Rev0.370877
Targeting CB2 cannabinoid0.338858
ancient cannabis from0.417929
Cannabidiol inhibits0.365208
Proc Natl Acad0.396634
canabinoides endógenos0.435834
cannabinoid receptor0.890303
CB2 receptor agonists0.350942
cannabis sativa l0.444025
Blázquez C0.343327
chemokine receptor cxcr40.338077
Cannabis sativa extract0.416057
cell proliferation0.33314
sistema nervioso central0.343143
breast cancer0.515229
Cannabis medicinal0.719247
receptores canabinoides0.400314
emerging target0.333482
Cannabis versus0.409865
agonistas canabinoides0.344588
CB2 cannabinoid0.361915
CLICK HERE
3879 National Cancer Institute Html es Extractos de muérdago (PDQ®)–Versión para pacientes Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer.
cuerpo frente0.413451
Centro Nacional0.449381
New Hampshire Avenue0.415853
cabo ensayos0.424385
Drug Administration0.409825
NCI Best Case0.428572
PDQ Extractos0.439937
Helixor A0.41291
datos bibliográficos pubmed0.416761
marcas comerciales eurixor0.426376
siguientes preguntas0.410006
productos botánicos0.410905
Polyerga Neu0.415135
solicitudes ind0.41359
cura lotodo0.415539
vitamina b0.413657
siguientes riesgos0.412404
Instituto Nacional0.532861
National Center0.412812
siguientes marcas0.416399
Salud Complementaria0.466538
idioma alemán0.413696
Visuals Online0.41151
complementarias revisa0.415619
Physician Data Query0.465832
Estados Unidos0.692378
mejores cuidados0.41274
libre uso0.41183
cabo estudios0.418615
Integrative Health0.413952
página manejo0.410784
¿El tratamiento0.420943
¿Los beneficios0.40989
juntos cam0.409184
respuesta corporal frente0.42523
Series Program0.409771
medicina complementaria0.946895
árbol hospedador0.450028
CLICK HERE
3899 National Cancer Institute Html en National Cancer Act of 1937 National Cancer Act of 1937, signed into law by President Franklin D. Roosevelt, created the National Cancer Institute.
general public0.367365
National Cancer Advisory0.528357
cancer control work0.436895
research projects0.391515
act0.566247
similar research0.476584
General its approval0.365736
federal government0.49191
Cancer Institute Act0.442221
appointed member0.370413
National Advisory Cancer0.52537
technical matters0.410467
prevention0.411559
human knowledge0.397925
diagnosis0.527183
non-communicable disease0.363394
Cancer Advisory Council0.437071
PUBLIC NO.0.367229
independent research institute0.437264
principal agency0.418501
similar research activities0.412381
treatment centers0.373224
National Cancer Act0.475787
treatment0.554492
valuable contributions0.393688
United States0.637137
methods0.412995
Institute consultation services0.410647
cause0.426942
training0.369834
Advisory Cancer Council0.524827
cancer research0.428314
private institutions0.416999
Franklin D. Roosevelt0.416988
Public Law0.367866
cancer experts0.38424
State health agencies0.402781
National Cancer Institute0.913007
official business0.397421
research institutions0.36768
Committee Report No.0.406179
approval0.369507
HR.7931. 75th Congress0.4075
acceptance conditional gifts0.395258
Cancer Investigations0.395678
Surgeon General0.940401
Public Health Service0.694963
75th congress0.416285
time0.374442
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.